HealthyNCT07373106
Short-term Effects of Broccoli-derived Glucoraphanin on Recovery From Eccentric Muscle Damage
A study testing broccoli powder consumption in people with Healthy, run by Lithuanian Sports University.
Trial summary
Eccentric exercise induces muscle damage and delay functional recovery. Broccoli-derived glucoraphanin (a sulforaphane precursor that activates Nrf2 defenses) may aid repair; however, its short-term effects in humans remains unknown. Read more about this study
- Who is it for?
- Ages 18 to 35 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- broccoli powder consumption
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 17 participants
- Where
- No sites listed yet
- Study dates
- 15 Feb 2026to 31 Mar 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- no resistance training experience in the past 6 months, no arm injuries in the past 2 years, no illnesses in the month prior to data collection, and no known allergies to broccoli or other cruciferous vegetables.
Who cannot join
- incomplete participation.
About this study
Official title: SHORT-TERM EFFECTS OF BROCCOLI-DERIVED GLUCORAPHANIN ON RECOVERY FROM ECCENTRIC MUSCLE DAMAGE: A DOUBLE-BLIND RANDOMIZED CROSSOVER STUDY
Eccentric exercise induces muscle damage and delay functional recovery. Broccoli-derived glucoraphanin (a sulforaphane precursor that activates Nrf2 defenses) may aid repair; however, its short-term effects in humans remains unknown. This study aims to evaluate whether short-term supplementation with broccoli-derived glucoraphanin will improve recovery from exercise-induced muscle damage. In a randomized, double-blind, placebo-controlled crossover design, fifteen participants will consume either high-glucoraphanin broccoli powder (320 μg) or placebo for one week, followed by elbow flexor eccentric exercise and continued supplementation. Strength, soreness, creatine kinase (CK), range of motion (ROM), arm girths, and ultrasound-assessed muscle and tendon morphology will be measured at baseline, immediately post-exercise, and at 48 and 96 hours post-exercise.
- Conditions
- Healthy
- Being tested
- broccoli powder consumption, Placebo (no broccoli-derived bioactives)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
broccoli powder consumptionDietary supplement
Participants underwent two separate sessions of muscle-damaging exercise targeting the elbow flexors: (1) following seven days of broccoli powder consumption (condition X), and (2) following an equivalent placebo regimen (condition Y). The broccoli supplementation consisted of 10 g of broccoli powder [a freeze-dried glucoraphanin-rich broccoli powder (99.5% broccoli and 0.5% mustard seed)] dissolved in 125 mL of boiling water, providing 320 μg of glucoraphanin per serving. It was consumed when still hot/warm once daily for seven days before and for four days following the eccentric exercise protocol. The placebo powder, matched in appearance and preparation, contained no broccoli-derived bioactives.
Placebo (no broccoli-derived bioactives)Dietary supplement
The placebo powder, matched in appearance and preparation, contained no broccoli-derived bioactives.
| Study group | Role | What they receive |
|---|---|---|
| male volunteers aged 18-35 years | Experimental | Not described Receives: Dietary Supplement: broccoli powder consumption; Dietary Supplement: Placebo (no broccoli-derived bioactives) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peak torque, Nm/s
Exercise induced damage marker, isokinetic and isometric knee extension
Measured: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.
Range of motion, degree
Exercise induced damage marker, elbow extension and flexion
Measured: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.
Arm girth, mm
Exercise induced muscle damage marker, arm relaxed and fully flexed
Measured: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.
Secondary outcomes (2)
Soreness, points
exercise induced damage marker, biceps brachii, 10-point visual analogue scale with 0 indicating no soreness and 10 indicating intolerably intense soreness.
Measured: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.
Creatine kinase, IU/L
Exercise induced muscle damage marker in venous blood
Measured: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2026
- Study start15 Feb 2026 (estimated)
- Primary completion15 Mar 2026 (estimated)
- Study completion31 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 17 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Lithuanian Sports University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07373106
- Sponsor's protocol ID
- MNLKIN(M)-2024-574
- Status last verified
- Jan 2026
- First submitted
- 15 Sep 2025
- Last updated
- 28 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SHORT-TERM EFFECTS OF BROCCOLI-DERIVED GLUCORAPHANIN ON RECOVERY FROM ECCENTRIC MUSCLE DAMAGE: A DOUBLE-BLIND RANDOMIZED CROSSOVER STUDY
- ClinicalTrials.gov ID
- NCT07373106
- Acronym / sponsor ID
- MNLKIN(M)-2024-574
- Conditions
- Healthy
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 17 participants (estimated)
- Lead sponsor
- Lithuanian Sports UniversityUniversity, hospital or other
- Study start
- 15 Feb 2026 (estimated)
- Primary completion
- 15 Mar 2026 (estimated)
- Study completion
- 31 Mar 2026 (estimated)
- First posted
- 28 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Eccentric exercise induces muscle damage and delay functional recovery. Broccoli-derived glucoraphanin (a sulforaphane precursor that activates Nrf2 defenses) may aid repair; however, its short-term effects in humans remains unknown. This study aims to evaluate whether short-term supplementation with broccoli-derived glucoraphanin will improve recovery from exercise-induced muscle damage. In a randomized, double-blind, placebo-controlled crossover design, fifteen participants will consume either high-glucoraphanin broccoli powder (320 μg) or placebo for one week, followed by elbow flexor eccentric exercise and continued supplementation. Strength, soreness, creatine kinase (CK), range of motion (ROM), arm girths, and ultrasound-assessed muscle and tendon morphology will be measured at baseline, immediately post-exercise, and at 48 and 96 hours post-exercise.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| male volunteers aged 18-35 years | Experimental | Dietary Supplement: broccoli powder consumption, Dietary Supplement: Placebo (no broccoli-derived bioactives) |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- no resistance training experience in the past 6 months, no arm injuries in the past 2 years, no illnesses in the month prior to data collection, and no known allergies to broccoli or other cruciferous vegetables.
Key exclusion criteria (1 listed)
- incomplete participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| broccoli powder consumptionParticipants underwent two separate sessions of muscle-damaging exercise targeting the elbow flexors: (1) following seven days of broccoli powder consumption (condition X), and (2) following an equivalent placebo regimen (condition Y). The broccoli supplementation consisted of 10 g of broccoli powder [a freeze-dried glucoraphanin-rich broccoli powder (99.5% broccoli and 0.5% mustard seed)] dissolved in 125 mL of boiling water, providing 320 μg of glucoraphanin per serving. It was consumed when still hot/warm once daily for seven days before and for four days following the eccentric exercise protocol. The placebo powder, matched in appearance and preparation, contained no broccoli-derived bioactives. | Dietary supplement | male volunteers aged 18-35 years |
| Placebo (no broccoli-derived bioactives)The placebo powder, matched in appearance and preparation, contained no broccoli-derived bioactives. | Dietary supplement | male volunteers aged 18-35 years |
Primary outcome
Peak torque, Nm/s
Time frame: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.
Exercise induced damage marker, isokinetic and isometric knee extension
Range of motion, degree
Time frame: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.
Exercise induced damage marker, elbow extension and flexion
Arm girth, mm
Time frame: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.
Exercise induced muscle damage marker, arm relaxed and fully flexed
2 secondary outcomes
Soreness, points
Time frame: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.
Creatine kinase, IU/L
Time frame: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2026.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing broccoli powder consumption in people with Healthy, run by Lithuanian Sports University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peak torque, Nm/s (time frame: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2026.